Bli medlem
Bli medlem

Du är här


New issue of CombiGenes newsletter Ingeniouis

Read CombiGenes newsletter here in english or download the attachement


Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63

Arne Ferstad, Chairman of the board
Phone: +447496526142
CombiGene AB (publ) Medicon Village, SE-223 81 Lund, Sweden

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies.

CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99,

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282


Ingeneious Nr2 2020

Författare CombiGene

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.